ArticleScientific reports2025
Uricosuric, antioxidant, and anti-inflammatory properties of Pandanus amaryllifolius Roxb. extract against potassium oxonate-induced hyperuricemia in rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
High serum uric acid (HUA) is linked to gout, fatty liver, and insulin resistance. Anti-hyperuricemic drugs were designed to lower uric acid production and/or inhibit urate reabsorption by renal and extra-renal tissues. While Pandanus amaryllifolius Roxb. ex Lindl. extract (PA) was reported to reduce uric acid production, the full effects of PA on urate metabolism were unclear. This study investigated PA impact on uric acid reabsorption and excretion in Wistar rats with potassium oxonate-induced HUA. Hyperuricemic rats showed elevated uric acid, reduced urinary excretion, decreased antioxidants, β-cell dysfunction, hyperglycemia, kidney damage, and hepatic fat. PA supplementation (0.5, 1, and 2 g/kg) for 14 days lowered serum xanthine oxidase activity and uric acid levels, comparable to benzbromarone and less potently than allopurinol. This reduction was achieved by suppressing urate reabsorption and enhancing renal and intestinal urate excretion. Furthermore, PA alleviated β-cell dysfunction and hyperglycemia by improving insulin secretion and signaling (IRS1 and Akt activation). It also reduced hepatic lipid synthesis, stimulated lipolysis, and decreased hepatic fat accumulation and pro-inflammatory cytokines. These findings demonstrate PA xanthine oxidase inhibitory, uricosuric, antioxidant, and anti-inflammatory properties, highlighting its potential as a therapeutic agent for hyperuricemia and related hyperglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.